CD34 + gene expression profiling of individual children with very severe aplastic anemia indicates a pathogenic role of integrin receptors and the proapoptotic death ligand TRAIL

Haematologica

Volumn 97, Issue 9, 2012, Pages 1304-1311

  Fischer, Ute ^a   Ruckert, Christian ^b   Hubner, Bernd ^a   Eckermann, Olaf ^a   Binder, Vera ^a   Bakchoul, Tamam ^c   Schuster, Friedhelm R ^a   Merk, Sylvia ^b   Klein, Hans Ulrich ^b   Führer, Monika ^d   Dugas, Martin ^b   Borkhardt, Arndt ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Autoantibodies; CD34 + stem cells; Integrins; Myelodysplastic syndrome; Very severe aplastic anemia

Indexed keywords

ALPHA2 INTEGRIN; BETA1 INTEGRIN; CD34 ANTIGEN; FAS ANTIGEN; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB; GLYCOPROTEIN VI; INTEGRIN RECEPTOR; INTERFERON; MESSENGER RNA; RANTES; STAT1 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; THROMBIN RECEPTOR; THROMBOCYTE ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; IMMUNOSUPPRESSIVE AGENT; INTEGRIN; TNFSF10 PROTEIN, HUMAN; TUMOR MARKER;

ADOLESCENT; APLASTIC ANEMIA; APOPTOSIS; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DNA HYBRIDIZATION; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MALE; NUCLEOTIDE SEQUENCE; PRESCHOOL CHILD; REFRACTORY ANEMIA; SCHOOL CHILD; TUMOR ESCAPE; UPREGULATION; ANEMIA, APLASTIC; ANEMIA, REFRACTORY; CASE CONTROL STUDY; COMPARATIVE STUDY; GENETICS; MICROARRAY ANALYSIS; PATHOLOGY; PROGNOSIS;

ADOLESCENT; ANEMIA, APLASTIC; ANEMIA, REFRACTORY; ANTIGENS, CD34; APOPTOSIS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTEGRINS; MALE; MICROARRAY ANALYSIS; PROGNOSIS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR MARKERS, BIOLOGICAL;

EID: 84865858649     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.056705     Document Type: Article

References (55)

1. Pellagatti A, Cazzola M, Giagounidis AA, Malcovati L, Porta MG, Killick S, et al. Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood. 2006;108(1):337-45.
2. Young NS, Bacigalupo A, Marsh JC. Aplastic anemia: pathophysiology and treatment. Biol Blood Marrow Transplant. 2010;16(1 Suppl):S119-25.
3. Hirano N, Butler MO, Von Bergwelt-Baildon MS, Maecker B, Schultze JL, O'Connor KC, et al. Autoantibodies frequently detected in patients with aplastic anemia. Blood. 2003;102(13):4567-75.
4. Feng X, Chuhjo T, Sugimori C, Kotani T, Lu X, Takami A, et al. Diazepam-binding inhibitor-related protein 1: a candidate autoantigen in acquired aplastic anemia patients harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells. Blood. 2004;104(8):2425-31.
5. Hirano N, Butler MO, Guinan EC, Nadler LM, Kojima S. Presence of anti-kinectin and anti-PMS1 antibodies in Japanese aplastic anaemia patients. Br J Haematol. 2005;128(2): 221-3.
6. Takamatsu H, Feng X, Chuhjo T, Lu X, Sugimori C, Okawa K, et al. Specific antibodies to moesin, a membrane-cytoskeleton linker protein, are frequently detected in patients with acquired aplastic anemia. Blood. 2007;109(6):2514-20.
7. Takamatsu H, Yagasaki H, Takahashi Y, Hama A, Saikawa Y, Yachie A, et al. Aplastic anemia successfully treated with rituximab: the possible role of aplastic anemia-associated autoantibodies as a marker for response. Eur J Haematol. 86(6):541-5.
8. Michel M, Lee K, Piette JC, Fromont P, Schaeffer A, Bierling P, et al. Platelet autoantibodies and lupus-associated thrombocytopenia. Br J Haematol. 2002;119(2):354-8.
9. Macchi L, Rispal P, Clofent-Sanchez G, Pellegrin JL, Nurden P, Leng B, et al. Antiplatelet antibodies in patients with systemic lupus erythematosus and the primary antiphospholipid antibody syndrome: their relationship with the observed thrombocytopenia. Br J Haematol. 1997;98(2):336-41.
10. Macmillan ML, Blazar BR, DeFor TE, Wagner JE. Transplantation of ex-vivo cultureexpanded parental haploidentical mesenchy-mal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial. Bone Marrow Transplant. 2009;43(6): 447-54.
11. Kaplan C. Foetal and neonatal alloimmune thrombocytopaenia. Orphanet J Rare Dis. 2006;1:39.
12. Wagers AJ, Allsopp RC, Weissman IL. Changes in integrin expression are associated with altered homing properties of Lin(-/lo)Thy1.1(lo)Sca-1(+)c-kit(+) hematopoietic stem cells following mobilization by cyclophosphamide/granulocyte colony-stimulating factor. Exp Hematol. 2002;30(2):176-85.
13. Vermeulen M, Le Pesteur F, Gagnerault MC, Mary JY, Sainteny F, Lepault F. Role of adhesion molecules in the homing and mobilization of murine hematopoietic stem and progenitor cells. Blood. 1998;92(3):894-900.
14. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110(6):673-87.
15. Zeng W, Chen G, Kajigaya S, Nunez O, Charrow A, Billings EM, et al. Gene expression profiling in CD34 cells to identify differences between aplastic anemia patients and healthy volunteers. Blood. 2004;103(1):325-32.
16. Philpott NJ, Scopes J, Marsh JC, Gordon-Smith EC, Gibson FM. Increased apoptosis in aplastic anemia bone marrow progenitor cells: possible pathophysiologic significance. Exp Hematol. 1995;23(14):1642-8.
17. Vibhuti, Tripathy NK, Nityanand S. Massive apoptosis of bone marrow cells in aplastic anaemia. Br J Haematol. 2002;117 (4):993-4.
18. Zeng W, Kajigaya S, Chen G, Risitano AM, Nunez O, Young NS. Transcript profile of CD4+ and CD8+ T cells from the bone marrow of acquired aplastic anemia patients. Exp Hematol. 2004;32(9):806-14.
19. Zeng W, Miyazato A, Chen G, Kajigaya S, Young NS, Maciejewski JP. Interferongamma-induced gene expression in CD34 cells: identification of pathologic cytokinespecific signature profiles. Blood. 2006;107(1):167-75.
20. Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther. 2005;4(2):139-63.
21. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 2003;10(1):66-75.
22. Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, et al. Apoptosis and interferons: role of interferonstimulated genes as mediators of apoptosis. Apoptosis. 2003;8(3):237-49.
23. Camitta BM, Rappeport JM, Parkman R, Nathan DG. Selection of patients for bone marrow transplantation in severe aplastic anemia. Blood. 1975;45(3):355-63.
24. Fuhrer M, Rampf U, Baumann I, Faldum A, Niemeyer C, Janka-Schaub G, et al. Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. Blood. 2005;106(6):2102-4.
25. Fuhrer M, Bender-Gotze C, Ebell W, Friedrich W, Kohne E. [Treatment of aplastic anemia--aims and development of the SAA 94 pilot protocol]. Klin Padiatr. 1994;206(4):289-95.
26. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2):249-64.
27. Smyth GK. Limma: linear models for microarray data. In: Gentleman R, Carey V, Huber W, Irizarry R, Dudoit S, (ed). Bioinformatics and computational biology solutions using R and bioconductor. New York: Springer, 2005:397-420.
28. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B (Methodological). 1995;57(1):289-300.
29. Mukherjee S. Classifying microarray data using support vector machines. In: Berrar DP, Dubitzky W, Granzow M, ed. A practical approach to microarray data analysis: Springer, 2003:1-20.
30. Kiefel V, Freitag E, Kroll H, Santoso S, Mueller-Eckhardt C. Platelet autoantibodies (IgG, IgM, IgA) against glycoproteins IIb/IIIa and Ib/IX in patients with thrombocytopenia. Ann Hematol. 1996;72(4):280-5.
31. Schneider W, Schnaidt M. The platelet adhesion immunofluorescence test: a modification of the platelet suspension immunofluorescence test. Blut. 1981;43(6):389-92.
32. Sloand E, Kim S, Maciejewski JP, Tisdale J, Follmann D, Young NS. Intracellular interferon-gamma in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia. Blood. 2002;100(4): 1185-91.
33. Tichelli A, Gratwohl A, Wursch A, Nissen C, Speck B. Late haematological complications in severe aplastic anaemia. Br J Haematol. 1988;69(3):413-8.
34. Shattil SJ, O'Toole T, Eigenthaler M, Thon V, Williams M, Babior BM, et al. Beta 3-endonexin, a novel polypeptide that interacts specifically with the cytoplasmic tail of the integrin beta 3 subunit. J Cell Biol. 1995;131 (3):807-16.
35. Zauli G, Secchiero P. The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. Cytokine Growth Factor Rev. 2006;17(4):245-57.
36. Kakagianni T, Giannakoulas NC, Thanopoulou E, Galani A, Michalopoulou S, Kouraklis-Symeonidis A, et al. A probable role for trail-induced apoptosis in the pathogenesis of marrow failure. Implications from an in vitro model and from marrow of aplastic anemia patients. Leuk Res. 2006;30(6):713-21.
37. Degli-Esposti MA, Smolak PJ, Walczak H, Waugh J, Huang CP, DuBose RF, et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med. 1997;186(7):1165-70.
38. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997;277(5327):818-21.
39. Grimm M, Kim M, Rosenwald A, von Rahden B, Tsaur I, Meier E, et al. Tumourmediated TRAIL-Receptor expression indicates effective apoptotic depletion of infiltrating CD8+ immune cells in clinical colorectal cancer. Eur J Cancer. 46(12):2314-23.
40. Giovarelli M, Musiani P, Garotta G, Ebner R, Di Carlo E, Kim Y, et al. A "stealth effect": adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions. J Immunol. 1999;163(9):4886-93.
41. Zhao S, Asgary Z, Wang Y, Goodwin R, Andreeff M, Younes A. Functional expression of TRAIL by lymphoid and myeloid tumour cells. Br J Haematol. 1999;106(3):827-32.
42. Koyama S, Koike N, Adachi S. Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor. J Cancer Res Clin Oncol. 2002;128 (2):73-9.
43. Shiraki K, Yamanaka T, Inoue H, Kawakita T, Enokimura N, Okano H, et al. Expression of TNF-related apoptosis-inducing ligand in human hepatocellular carcinoma. Int J Oncol. 2005;26(5):1273-81.
44. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: cancer as a site of immune privilege. Immunol Today. 1999;20(1):46-52.
45. Wajant H. CD95L/FasL and TRAIL in tumour surveillance and cancer therapy. Cancer Treat Res. 2006;130:141-65.
46. Carlo-Stella C, Lavazza C, Di Nicola M, Cleris L, Longoni P, Milanesi M, et al. Antitumor activity of human CD34+ cells expressing membrane-bound tumor necrosis factor-related apoptosis-inducing ligand. Hum Gene Ther. 2006;17(12):1225-40.
47. Carlo-Stella C, Lavazza C, Locatelli A, Vigano L, Gianni AM, Gianni L. Targeting TRAIL agonistic receptors for cancer therapy. Clin Cancer Res. 2007;13(8):2313-7.
48. Secchiero P, Melloni E, Heikinheimo M, Mannisto S, Di Pietro R, Iacone A, et al. TRAIL regulates normal erythroid maturation through an ERK-dependent pathway. Blood. 2004;103(2):517-22.
49. Pigullo S, Ferretti E, Lanciotti M, Bruschi M, Candiano G, Svahn J, et al. Human Fanconi A cells are susceptible to TRAIL-induced apoptosis. Br J Haematol. 2007;136(2):315-8.
50. Campioni D, Secchiero P, Corallini F, Melloni E, Capitani S, Lanza F, et al. Evidence for a role of TNF-related apoptosisinducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. Am J Pathol. 2005;166(2):557-63.
51. Beardsley DS, Ertem M. Platelet autoantibodies in immune thrombocytopenic purpura. Transfus Sci. 1998;19(3):237-44.
52. McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 2004;103(4):1364-9.
53. Chang M, Nakagawa PA, Williams SA, Schwartz MR, Imfeld KL, Buzby JS, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood. 2003;102(3):887-95.
54. Houwerzijl EJ, Blom NR, van der Want JJ, Esselink MT, Koornstra JJ, Smit JW, et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood. 2004;103(2):500-6.
55. McMillan R. The pathogenesis of chronic immune thrombocytopenic purpura. Semin Hematol. 2007;44(4 Suppl 5):S3-S11.